Suda Pharmaceuticals Ltd RSI
What is the RSI of Suda Pharmaceuticals Ltd?
The RSI of Suda Pharmaceuticals Ltd is 42.29
What is the definition of RSI?
The relative strength index (RSI 14) is a momentum indicator that compares the magnitude of gains and losses over a specified time period to measure speed and change of price movements of a security.
14-day period
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI of companies in the Health Care sector on ASX compared to Suda Pharmaceuticals Ltd
What does Suda Pharmaceuticals Ltd do?
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Companies with rsi similar to Suda Pharmaceuticals Ltd
- Millennial Precious Metals Corp has RSI of 42.28
- HT Media has RSI of 42.28
- PTC Therapeutics Inc has RSI of 42.28
- Arfin India has RSI of 42.28
- Lindian Resources has RSI of 42.28
- Dateline Resources has RSI of 42.28
- Suda Pharmaceuticals Ltd has RSI of 42.29
- Matson Inc has RSI of 42.30
- Bold Ventures has RSI of 42.30
- Purpose Bitcoin ETF has RSI of 42.30
- Sokoman Minerals has RSI of 42.30
- China Shandong Hi-Speed has RSI of 42.30
- Walt Disney Co has RSI of 42.30